Converge Bio Secures $25M to Advance AI-Driven Drug Discovery with Support from Top Tech Executives
Converge Bio, an AI-focused drug discovery startup, has raised $25 million in a Series A funding round led by Bessemer Venture Partners, with additional investments from executives at Meta, OpenAI, and Wiz, signaling strong confidence in AI’s role in transforming healthcare.
